SYS-CON MEDIA Authors: Elizabeth White, Pat Romanski, Mat Mathews, PR.com Newswire, David Smith

News Feed Item

Product Clearance, Appointments, Upcoming Financial Results, and Clinical Study Results - Analyst Notes on Covidien, Medivation, United Therapeutics, Questcor and CareFusion

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 25, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Medivation, Inc. (NASDAQ: MDVN), United Therapeutics Corporation (NASDAQ: UTHR), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1611-100free.

--
Covidien plc Analyst Notes
On April 14, 2014, Covidien plc (Covidien) announced the U.S. Food and Drug Administration (FDA) Clearance for the Kangaroo™ feeding tube with Integrated Real-time Imaging System (IRIS) Technology, the first-of-its-kind camera-equipped disposable feeding tube designed to enhance patient safety. The Company stated that the Covidien IRIS streams a real-time video back to the monitor, providing visual information that aids clinicians in identifying key areas of a patient's anatomy and also enables medical professionals in saving images from the live stream and making notes associated with the image. Jim Clemmer, President, Medical Supplies, Covidien, said, "Covidien is an industry leader in nutritional delivery and enteral feeding devices and products such as the Kangaroo feeding tube with IRIS technology are designed to help improve patient outcomes and set new expectations for medical device product safety and innovation around the world." The full analyst notes on Covidien are available to download free of charge at:

http://www.analystsreview.com/1611-COV-25Apr2014.pdf

--
Medivation, Inc. Analyst Notes
On April 17, 2014, Medivation, Inc. (Medivation) announced the appointment of Patrick Machado to the Company's Board of Directors, who recently retired as the Chief Financial and Business Officer. Commenting on the appointment, Kim D. Blickenstaff, Chairman, Medivation, said, "For the past nine years of having the honor of serving on the board of directors of Medivation, including seven as chairman, I've had the opportunity to observe the keen insight and vision that Pat Machado has brought to Medivation. I look forward to working with Pat in his new role, as he continues to help guide Medivation's efforts to develop novel therapies for serious diseases." The full analyst notes on Medivation are available to download free of charge at:

http://www.analystsreview.com/1611-MDVN-25Apr2014.pdf

--
United Therapeutics Corporation Analyst Notes
On April 22, 2014, United Therapeutics Corporation (United Therapeutics) announced that it will release its Q1 2014 financial results on April 29, 2014, before the market opens. The Company added that it will hold a half-hour teleconference on April 29, 2014, at 9:00 a.m. ET. United Therapeutics stated that the teleconference will be webcast and can be accessed via its website. The full analyst notes on United Therapeutics are available to download free of charge at:

http://www.analystsreview.com/1611-UTHR-25Apr2014.pdf

--
Questcor Pharmaceuticals, Inc. Analyst Notes
On April 21, 2014, Questcor Pharmaceuticals, Inc. (Questcor) announced results from an investigator-initiated clinical study that examined the dosing and effectiveness of H.P. Acthar® Gel in 20 patients with nephrotic syndrome due to idiopathic membranous nephropathy (iMN). According to the Company, the results demonstrated that Acthar Gel is proven to be a potentially useful therapy for inducing remission of proteinuria in patients suffering from nephrotic syndrome secondary to iMN. Questcor added that the study also showed that the clearance of anti-PLA2R antibodies, an immunological marker of iMN disease activity, preceded or paralleled improvements in proteinuria as a result of Acthar treatment in patients with detectable antibody levels. The Company further stated that Acthar Gel was well tolerated by patients during the course of the study, with the most common side effects being mood changes, weight gain, and transient insomnia. The full analyst notes on Questcor are available to download free of charge at:

http://www.analystsreview.com/1611-QCOR-25Apr2014.pdf

--
CareFusion Corporation Analyst Notes
On April 7, 2014, CareFusion Corporation (CareFusion) announced that it plans to release its Q3 FY 2014 financial results on May 5, 2014, after the close of trading on the New York Stock Exchange. The Company added that it will also host a conference call on the same day at 2:00 p.m. PDT (5:00 p.m. EDT). CareFusion stated that the call will be made accessible through the Investors Page of the Company website. The full analyst notes on CareFusion are available to download free of charge at:

http://www.analystsreview.com/1611-CFN-25Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.